$599

Lilly Publishes TRIUMPH-1 and TRIUMPH-2 OSA Results; Abbott Q3 ’26 Earnings; Novo Wegovy Pill France Launch; ADA CSO/CMO Transition

A series of cardiometabolic-related news items has been observed from Lilly, Abbott, Novo, and ADA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here